{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=15",
    "query": {
      "condition": "Urogenital Neoplasms",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 8974,
    "total_pages": 898,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:39:53.977Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04266431",
      "title": "EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "EMPOWER",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2020-02-20",
      "completion_date": "2025-02-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-12",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04266431"
    },
    {
      "nct_id": "NCT01853046",
      "title": "Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Regorafenib (Stivarga, BAY73-4506)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-06",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-20",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853046"
    },
    {
      "nct_id": "NCT00117286",
      "title": "Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 57,
      "start_date": "2005-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 17,
      "location_summary": "Homewood, Alabama • Anaheim, California • Tarzana, California + 14 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117286"
    },
    {
      "nct_id": "NCT01484873",
      "title": "Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Overweight",
        "Craniopharyngioma"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484873"
    },
    {
      "nct_id": "NCT05092022",
      "title": "St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer Screening"
      ],
      "interventions": [
        {
          "name": "Evalyn Self-Sampling Brush",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 65 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2023-09-18",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 1,
      "location_summary": "Reading, Pennsylvania",
      "locations": [
        {
          "city": "Reading",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092022"
    },
    {
      "nct_id": "NCT02378922",
      "title": "Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Hodgkin Lymphoma",
        "AIDS-Related Non-Hodgkin Lymphoma",
        "HIV Infection",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Gene-Modified HIV-Protected Hematopoietic Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Transplant Conditioning",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-06-22",
      "completion_date": "2019-06-15",
      "has_results": false,
      "last_update_posted_date": "2018-12-27",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378922"
    },
    {
      "nct_id": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive",
        "Adenocarcinoma",
        "Bile Duct Cancer",
        "Biliary Tract Cancer",
        "Bladder Cancer",
        "Breast Cancer",
        "Breast Neoplasm",
        "Carcinoma, Ductal",
        "Carcinoma, Hepatocellular",
        "Cancer",
        "Lung Cancer, Non-Small-Cell",
        "Carcinoma, Ovarian Epithelial",
        "Carcinoma, Small Cell",
        "Carcinoma, Squamous",
        "Carcinoma, Transitional Cell",
        "Colorectal Cancer",
        "Esophagogastric Junction Neoplasms",
        "Inflammatory Breast Cancer",
        "Stomach Neoplasms",
        "Malignant Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER-2 Protein Overexpression",
        "HER-2 Gene Amplification",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Endometrial Cancer",
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "CT-0508",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-02",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660929"
    },
    {
      "nct_id": "NCT00473746",
      "title": "Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Neoplasms"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "prednisone/prednisolone or dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 66,
      "start_date": "2006-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473746"
    },
    {
      "nct_id": "NCT00003588",
      "title": "Gene Therapy in Treating Patients With Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Ad5CMV-p53 gene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laparoscopic surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "1998-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-08",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003588"
    },
    {
      "nct_id": "NCT07322094",
      "title": "CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FIGO Stage III and IV Ovarian Cancer",
        "Fallopian Tube Cancers",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "TORL-1-23 and paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TORL-1-23 and carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TORL-1-23, paclitaxel, and carboplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "TORL Biotherapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-10",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-15T00:39:53.977Z",
      "location_count": 7,
      "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07322094"
    }
  ]
}